Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report) CFO Michael Truett Tate sold 100,000 shares of the business’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $62.03, for a total transaction of $6,203,000.00. Following the completion of the transaction, the chief financial officer now owns 1,762,888 shares in the company, valued at approximately $109,351,942.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Michael Truett Tate also recently made the following trade(s):
- On Thursday, August 29th, Michael Truett Tate sold 50,000 shares of Astera Labs stock. The shares were sold at an average price of $47.98, for a total transaction of $2,399,000.00.
Astera Labs Stock Up 0.9 %
Shares of NASDAQ:ALAB opened at $66.69 on Friday. Astera Labs, Inc. has a 52 week low of $36.22 and a 52 week high of $95.21. The company has a 50 day moving average price of $45.84 and a two-hundred day moving average price of $58.36.
Institutional Investors Weigh In On Astera Labs
Large investors have recently made changes to their positions in the stock. Sei Investments Co. bought a new stake in shares of Astera Labs during the first quarter worth $952,000. Vanguard Group Inc. bought a new stake in shares of Astera Labs during the first quarter worth $127,268,000. Forge First Asset Management Inc. bought a new stake in shares of Astera Labs during the first quarter worth $1,143,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Astera Labs during the first quarter worth $44,514,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in Astera Labs during the first quarter worth $18,666,000.
Analyst Ratings Changes
ALAB has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Astera Labs from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Barclays reduced their price target on shares of Astera Labs from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Stifel Nicolaus reduced their target price on shares of Astera Labs from $87.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, August 5th. JPMorgan Chase & Co. reduced their target price on shares of Astera Labs from $95.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Finally, Morgan Stanley upped their target price on shares of Astera Labs from $55.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday. Eleven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $73.09.
View Our Latest Analysis on Astera Labs
Astera Labs Company Profile
Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.
Read More
- Five stocks we like better than Astera Labs
- Overbought Stocks Explained: Should You Trade Them?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- 10 Best Airline Stocks to Buy
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.